Codexis (CDXS) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Codexis Reports Financial Results for the Second Quarter of 2015
August 11, 2015 4:05 PM EDT-- Raises 2015 revenue and gross margin guidance to reflect recent licensing transaction with Merck --
-- Conference call begins at 4:30 p.m. Eastern time today --
REDWOOD CITY, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces financial results for the three and six months ended June 30, 2015, and raises its revenue and gross margin outlook for 2015.
"Solid year-to-date progress executing our plans encourages us to raise both of our annual... More
Codexis Reports Financial Results for the Second Quarter of 2015
August 11, 2015 4:05 PM EDT-- Raises 2015 revenue and gross margin guidance to reflect recent licensing transaction with Merck --
-- Conference call begins at 4:30 p.m. Eastern time today --
REDWOOD CITY, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces financial results for the three and six months ended June 30, 2015, and raises its revenue and gross margin outlook for 2015.
"Solid year-to-date progress executing our plans encourages us to raise both of our annual... More
Codexis Collaborates With Leading Biopharmaceutical Company to Apply CodeEvolver Protein Engineering in Therapeutics Development Program
August 11, 2015 7:00 AM EDTREDWOOD CITY, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, today announced that it has entered into a collaborative research and development agreement with a leading global biopharmaceutical company. This is the first significant agreement in which Codexis will apply its proprietary CodeEvolver® protein engineering platform technology with a company in the biopharmaceutical industry.
Under the terms of the agreement, Codexis will employ CodeEvolver to develop a novel enzyme for use in its partner's preclinical therapeutic development program. Development of the new enzyme will occur in... More
Codexis Collaborates With Leading Biopharmaceutical Company to Apply CodeEvolver Protein Engineering in Therapeutics Development Program
August 11, 2015 7:00 AM EDTREDWOOD CITY, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, today announced that it has entered into a collaborative research and development agreement with a leading global biopharmaceutical company. This is the first significant agreement in which Codexis will apply its proprietary CodeEvolver® protein engineering platform technology with a company in the biopharmaceutical industry.
Under the terms of the agreement, Codexis will employ CodeEvolver to develop a novel enzyme for use in its partner's preclinical therapeutic development program. Development of the new enzyme will occur in... More
